Please ensure Javascript is enabled for purposes of website accessibility

Why Cara Therapeutics Stock Jumped 15.1% in March

By Beth McKenna - Apr 9, 2019 at 7:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This small biotech expects to announce results from two clinical studies in 2019.

What happened

Shares of Cara Therapeutics (CARA 2.96%), a clinical-stage biotech, popped 15.1% in March, according to data from S&P Global Market Intelligence. For context, the S&P 500, including dividends, rose 1.9% last month. 

This month, the stock has tacked on another 2.8% through April 8, bringing its gain to 55.1% so far in 2019. The S&P 500 has returned 16.1% over this period. 

Female doctor looking at a clipboard.

Image source: Getty Images.

So what

On March 13, shares of Cara jumped 11.8% following the company's release the day before of its fourth-quarter and full-year 2018 results.

Its quarterly loss of $0.52 per share was better than the $0.58-per-share loss that Wall Street was expecting. But the stock's gain probably had more to do with investor optimism following the earnings call about the prospects for Cara's lead candidate, Korsuva. The drug's intravenous formulation is currently in a phase 3 clinical trial for treating pruritus (itching) in patients with chronic kidney disease who are on dialysis, while its oral formulation is in a phase 2 trial for the same indication in patients who aren't on dialysis. The company expects to announce the results from both studies this year.

Moreover, Cara expects to "broaden [its] clinical pruritus program for Oral KORSUVA with the initiation of Phase 2 trials in both liver disease and dermatological conditions, including atopic dermatitis," according to its earnings release. 

CARA Chart

Data by YCharts.

Now what 

As my colleague Maxx Chatsko wrote, "If the phase 3 trials for the injectable formulation prove successful, then the pharma company would be eligible to receive up to $470 million in milestone payments plus royalties on all sales" from its partner on the lead program, Fresenius Medical Care Renal Pharma.

Some analysts project that Korsuva could generate annual sales of more than $500 million in just the U.S. alone in treating chronic kidney disease-associated pruritus (CKD-aP), according to fellow Motley Fool contributor Keith Speights. Given that Cara's current market cap is just shy of $800 million, it's easy to see why some investors are enthused about the company's growth potential.

That said, as with all clinical-stage biotechs, Cara's stock is risky, as there's no guarantee the company's current or future drug candidates will come to market.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Cara Therapeutics, Inc. Stock Quote
Cara Therapeutics, Inc.
CARA
$9.39 (2.96%) $0.27

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.